Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-06-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/0300060518757640 |
| _version_ | 1828957766949011456 |
|---|---|
| author | Jun Xia Lingling Wang Xin Zhou Jing Wang Huan Wang Hongfeng Guo |
| author_facet | Jun Xia Lingling Wang Xin Zhou Jing Wang Huan Wang Hongfeng Guo |
| author_sort | Jun Xia |
| collection | DOAJ |
| description | Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. Conclusion Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes. |
| first_indexed | 2024-12-14T08:35:03Z |
| format | Article |
| id | doaj.art-371da912fadc4febb69141a18b526f8b |
| institution | Directory Open Access Journal |
| issn | 0300-0605 1473-2300 |
| language | English |
| last_indexed | 2024-12-14T08:35:03Z |
| publishDate | 2018-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-371da912fadc4febb69141a18b526f8b2022-12-21T23:09:25ZengSAGE PublishingJournal of International Medical Research0300-06051473-23002018-06-014610.1177/0300060518757640Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practiceJun XiaLingling WangXin ZhouJing WangHuan WangHongfeng GuoObjectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. Conclusion Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes.https://doi.org/10.1177/0300060518757640 |
| spellingShingle | Jun Xia Lingling Wang Xin Zhou Jing Wang Huan Wang Hongfeng Guo Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice Journal of International Medical Research |
| title | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
| title_full | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
| title_fullStr | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
| title_full_unstemmed | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
| title_short | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
| title_sort | early mortality in elderly patients undergoing treatment for multiple myeloma in real world practice |
| url | https://doi.org/10.1177/0300060518757640 |
| work_keys_str_mv | AT junxia earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT linglingwang earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT xinzhou earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT jingwang earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT huanwang earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT hongfengguo earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice |